close to approving another new drug for obesity

December 1996

The FDA is getting close to approving another new drug for obesity...Meridia (sibutramine) from Knoll.

Meridia inhibits the reuptake of serotonin and norepinephrine. It's in the same class as the antidepressant Effexor (venlafaxine).

In fact, Meridia was originally developed for use as an antidepressant. The manufacturer switched gears when they noticed that it causes weight loss. The weight loss market is a lot less crowded than the antidepressant market.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote